766 related articles for article (PubMed ID: 30550232)
1. Emodin Reduces the Activity of (1,3)-
Janeczko M
Pol J Microbiol; 2018; 67(4):463-470. PubMed ID: 30550232
[TBL] [Abstract][Full Text] [Related]
2. Identification of New Antifungal Agents Targeting Chitin Synthesis by a Chemical-Genetic Method.
Li Y; Sun H; Zhu X; Bian C; Wang Y; Si S
Molecules; 2019 Aug; 24(17):. PubMed ID: 31470665
[TBL] [Abstract][Full Text] [Related]
3. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
Park S; Kelly R; Kahn JN; Robles J; Hsu MJ; Register E; Li W; Vyas V; Fan H; Abruzzo G; Flattery A; Gill C; Chrebet G; Parent SA; Kurtz M; Teppler H; Douglas CM; Perlin DS
Antimicrob Agents Chemother; 2005 Aug; 49(8):3264-73. PubMed ID: 16048935
[TBL] [Abstract][Full Text] [Related]
4. Antifungal Activity of Salvia miltiorrhiza Against Candida albicans Is Associated with the Alteration of Membrane Permeability and (1,3)-β-D-Glucan Synthase Activity.
Lee HS; Kim Y
J Microbiol Biotechnol; 2016 Mar; 26(3):610-7. PubMed ID: 26699747
[TBL] [Abstract][Full Text] [Related]
5. Caspofungin-induced β(1,3)-glucan exposure in
Wagner AS; Lumsdaine SW; Mangrum MM; Reynolds TB
mBio; 2023 Aug; 14(4):e0007423. PubMed ID: 37377417
[TBL] [Abstract][Full Text] [Related]
6. Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment.
Wheeler RT; Kombe D; Agarwala SD; Fink GR
PLoS Pathog; 2008 Dec; 4(12):e1000227. PubMed ID: 19057660
[TBL] [Abstract][Full Text] [Related]
7. Piperazine propanol derivative as a novel antifungal targeting 1,3-beta-D-glucan synthase.
Kondoh O; Inagaki Y; Fukuda H; Mizuguchi E; Ohya Y; Arisawa M; Shimma N; Aoki Y; Sakaitani M; Watanabe T
Biol Pharm Bull; 2005 Nov; 28(11):2138-41. PubMed ID: 16272705
[TBL] [Abstract][Full Text] [Related]
8. Synergy of the antibiotic colistin with echinocandin antifungals in Candida species.
Zeidler U; Bougnoux ME; Lupan A; Helynck O; Doyen A; Garcia Z; Sertour N; Clavaud C; Munier-Lehmann H; Saveanu C; d'Enfert C
J Antimicrob Chemother; 2013 Jun; 68(6):1285-96. PubMed ID: 23378416
[TBL] [Abstract][Full Text] [Related]
9. Caspofungin resistance in Candida albicans: genetic factors and synergistic compounds for combination therapies.
Perrine-Walker F
Braz J Microbiol; 2022 Sep; 53(3):1101-1113. PubMed ID: 35352319
[TBL] [Abstract][Full Text] [Related]
10. Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agents.
Hoehamer CF; Cummings ED; Hilliard GM; Rogers PD
Antimicrob Agents Chemother; 2010 May; 54(5):1655-64. PubMed ID: 20145080
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence.
Rueda C; Cuenca-Estrella M; Zaragoza O
Antimicrob Agents Chemother; 2014; 58(2):1071-83. PubMed ID: 24295973
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors.
Onishi J; Meinz M; Thompson J; Curotto J; Dreikorn S; Rosenbach M; Douglas C; Abruzzo G; Flattery A; Kong L; Cabello A; Vicente F; Pelaez F; Diez MT; Martin I; Bills G; Giacobbe R; Dombrowski A; Schwartz R; Morris S; Harris G; Tsipouras A; Wilson K; Kurtz MB
Antimicrob Agents Chemother; 2000 Feb; 44(2):368-77. PubMed ID: 10639364
[TBL] [Abstract][Full Text] [Related]
13. Acquired resistance to echinocandins in Candida albicans: case report and review.
Baixench MT; Aoun N; Desnos-Ollivier M; Garcia-Hermoso D; Bretagne S; Ramires S; Piketty C; Dannaoui E
J Antimicrob Chemother; 2007 Jun; 59(6):1076-83. PubMed ID: 17468115
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans.
Chen YL; Lehman VN; Averette AF; Perfect JR; Heitman J
PLoS One; 2013; 8(3):e57672. PubMed ID: 23472097
[TBL] [Abstract][Full Text] [Related]
15. Nanoscale effects of caspofungin against two yeast species, Saccharomyces cerevisiae and Candida albicans.
Formosa C; Schiavone M; Martin-Yken H; François JM; Duval RE; Dague E
Antimicrob Agents Chemother; 2013 Aug; 57(8):3498-506. PubMed ID: 23669379
[TBL] [Abstract][Full Text] [Related]
16. Micafungin Enhances the Human Macrophage Response to Candida albicans through β-Glucan Exposure.
Guirao-Abad JP; Sánchez-Fresneda R; Machado F; Argüelles JC; Martínez-Esparza M
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483123
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the Localization of
San-Quirico E; Curto MÁ; Gómez-Delgado L; Moreno MB; Pérez P; Ribas JC; Cortés JCG
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901728
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance.
Bachmann SP; Patterson TF; López-Ribot JL
J Clin Microbiol; 2002 Jun; 40(6):2228-30. PubMed ID: 12037093
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of echinocandin antifungal drug resistance.
Perlin DS
Ann N Y Acad Sci; 2015 Sep; 1354(1):1-11. PubMed ID: 26190298
[TBL] [Abstract][Full Text] [Related]
20. Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins.
Maligie MA; Selitrennikoff CP
Antimicrob Agents Chemother; 2005 Jul; 49(7):2851-6. PubMed ID: 15980360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
